History of weight and obesity through life and risk of benign prostatic hyperplasia

International Journal of Obesity

Volumn 29, Issue 7, 2005, Pages 798-803

  Zucchetto, A ^a   Tavani, A ^b   Dal Maso, L ^a   Gallus, S ^b   Negri, E ^b   Talamini, R ^a   Franceschi, S ^c   Montella, M ^d   La Vecchia, C ^b,e  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Anthropometric measures; Benign prostatic hyperplasia; Case control studies; Diabetes; Hyperlipidemia; Hypertension

Indexed keywords

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY WEIGHT; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; HIP; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RISK ASSESSMENT; SELF REPORT; TESTOSTERONE BLOOD LEVEL; WAIST CIRCUMFERENCE;

AGED; BODY MASS INDEX; BODY WEIGHT; EPIDEMIOLOGIC METHODS; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; OBESITY; PROSTATIC HYPERPLASIA; WAIST-HIP RATIO;

EID: 21244473633     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802979     Document Type: Article

References (40)

1. Guess HA. Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev 1992; 14: 131-153.
2. Glynn RJ, Campion EW, Bouchard GR, Silbert JE. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol 1985; 121: 78-90.
3. Sidney S, Quesenberry Jr C, Sadler MC, Lydick EG, Guess HA, Cattolica EV. Risk factors for surgically treated benign prostatic hyperplasia in a prepaid health care plan. Urology 1991; 38 (Suppl 1): 13-19.
4. Seitter WR, Barrett-Connor E. Cigarette smoking, obesity, and benign prostatic hypertrophy: a prospective population-based study. Am J Epidemiol 1992; 135: 500-503.
5. Meigs JB, Mohr B, Barry MJ, McNaughton Collins M, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001; 54: 935-944.
6. Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA, Stampfer MJ, Willett WC. Obesity and benign prostatic hyperplasia. Am J Epidemiol 1994; 140: 989-1002.
7. Signorello LB, Tzonou A, Lagiou P, Samoli E, Zavitsanos X, Trichopoulos D. The epidemiology of benign prostatic hyperplasia. A study in Greece. BJU Int 1999; 84: 286-291.
8. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002; 168: 599-604.
9. Sarma AV, Jaffe CA, Schottenfeld D, Dunn R, Montie JE, Cooney KA, Wei JT. Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among black men. Urology 2002; 59: 362-367.
10. Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999; 8: 29-36.
11. Ando S, Rubens R, Rottiers R. Androgen plasma levels in male diabetics. J Endocrinol Invest 1984; 7: 21-24.
12. Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Sesterhenn IA, Mostofi FK, Fraumeni Jr JF, Hsing AW. Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate 2002; 52: 98-105.
13. Decarli A, Franceschi S, Ferraroni M, Gnagnarella P, Parpinel MT, La Vecchia C, Negri E, Salvini S, Falcini F, Giacosa A. Validation of a food-frequency questionnaire to assess dietary intakes in cancer studies in Italy. Results for specific nutrients. Ann Epidemiol 1996; 6: 110-118.
14. Tavani A, Braga C, La Vecchia C, Conti E, Filiberti R, Montella M, Amadori D, Russo A, Franceschi S. Physical activity and risk of cancers of the colon and rectum: an Italian case-control study. Br J Cancer 1999; 79: 1912-1916.
15. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. IARC Sci Publ 1980; 32: 5-338.
16. Begg CB. Methodological issues in studies of the treatment, diagnosis, and etiology of prostate cancer. Semin Oncol 1994; 21: 569-579.
17. Bosetti C, Tavani A, Negri E, Trichopoulos D, La Vecchia C. Reliability of data on medical conditions, menstrual and reproductive history provided by hospital controls. J Clin Epidemiol 2001; 54: 902-906.
18. Stewart AL. The reliability and validity of self-reported weight and height. J Chronic Dis 1982; 35: 295-309.
19. Millar WJ. Distribution of body weight and height: comparison of estimates based on self-reported and observed measures. J Epidemiol Community Health 1986; 40: 319-323.
20. Palta M, Prineas RJ, Berman R, Hannan P. Comparison of self-reported and measured height and weight. Am J Epidemiol 1982; 115: 223-230.
21. Kuskowska-Wolk A, Karlsson P, Stolt M, Rossner S. The predictive validity of body mass index based on self-reported weight and height. Int J Obes 1989; 13: 441-453.
22. Casey VA, Dwyer JT, Berkey CS, Coleman KA, Gardner J, Valadian I. Long-term memory of body weight and past weight satisfaction: a longitudinal follow-up study. Am J Clin Nutr 1991; 53: 1493-1498.
23. Klipstein-Grobusch K, Kroke A, Boeing H. Reproducibility of self-reported past body weight. Eur J Clin Nutr 1998; 52: 525-528.
24. Dal Maso L, Zucchetto A, La Vecchia C, Montella M, Conti E, Canzonieri V, Talamini R, Tavani A, Negri E, Garbeglio A, Franceschi S. Prostate cancer and body size at different ages: an Italian multicentre case-control study. Br J Cancer 2004; 90: 2176-2180.
25. MacDonald PC, Edman CD, Hemsell DL, Porter JC, Siiteri PK. Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 1978; 130: 448-455.
26. Kyprianou N, Davies P. Association states of androgen receptors in nuclei of human benign hypertrophic prostate. Prostate 1986; 8: 363-380.
27. Frydenberg M, Foo TM, Jones AS, Grace J, Hensley WJ, Rogers J, Pearson BS, Raghavan D. Benign prostatic hyperplasia-video image analysis and its relationship to androgen and epidermal growth factor receptor expression. J Urol 1991; 146: 872-876.
28. Ross RK, Schottenfeld D. Prostate cancer. In: Schottenfeld D, Fraumeni Jr JF (eds) Cancer Epidemiology and Prevention, 2nd edn. Oxford University Press: New York; 1996. pp 1180-1206.
29. Roberts RO, Bergstralh EJ, Cunningham JM, Hebbring SJ, Thibodeau SN, Lieber MM, Jacobsen SJ. Androgen receptor gene polymorphisms and increased risk of urologic measures of benign prostatic hyperplasia. Am J Epidemiol 2004; 159: 269-276.
30. Joseph MA, Harlow SD, Wei JT, Sarma AV, Dunn RL, Taylor JM, James SA, Cooney KA, Doerr KM, Montie JE, Schottenfeld D. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol 2003; 157: 906-914.
31. Lee E, Park MS, Shin C, Lee H, Yoo K, Kim Y, Shin Y, Paik HY, Lee C. A high-risk group for prostatism: a population-based epidemiological study in Korea. Br J Urol 1997; 79: 736-741.
32. McConnell JD, Roehrborn CG, Bautista OM, Andriole Jr GL, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg Jr LM, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-2398.
33. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman Jr CA. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-224.
34. Wilson JD. The pathogenesis of benign prostatic hyperplasia. Am J Med 1980; 68: 745-756.
35. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid Salpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186: 1213-1215.
36. Andersson S, Berman DM, Jenkins EP, Russell DW. Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. Nature 1991; 354: 159-161.
37. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J, Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. 1992. J Urol 2002; 167: 1102-1107.
38. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338: 557-563.
39. Platz EA, Kawachi I, Rimm EB, Longcope C, Stampfer MJ, Willett WC, Giovannucci E. Plasma steroid hormones, surgery for benign prostatic hyperplasia, and severe lower urinary tract symptoms. Prostate Cancer Prostatic Dis 1999; 2: 285-289.
40. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami H-O. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997; 76: 1115-1118.